Disorders characterized by ischemia/reperfusion, such as myocardial infarction, stroke, and peripheral vascular disease, continue to be among the most frequent causes of debilitating disease and death. Currently, no broad and effective therapeutic approaches are available most of all due to the very short timeframe (3-6 hours) from stroke symptom onset in which a patient is eligible to receive the tissue plasminogen activator, the only thrombolytic agent able to reduce the secondary effects of ischemia.
The Italian public medical research centre has selected and isolated human mesenchymal stem cells, renowned for their beneficial effects in pathological contexts of acute damage. After a reprogramming process (repCBMSC), the researchers identified a specific set of microRNA (miRNA) able to modulate inflammation in both parental Cord Blood Mesenchymal Stromal Cells - Extracellular vesicles (CBMSC-EV) and Reprogrammed Cord Blood Mesenchymal Stromal Cells - Extracellular vesicles (repCBMSC-EV). This set of miRNA was successfully challenged in a model of brain ischemia, where necrosis was significantly reduced.
The Italian medical research centre is looking for industrial partners interested in a licensing agreement of the technology or in technical agreement for co-development.